Published in Anticancer Res on January 29, 2003
The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol (2008) 1.93
Single nucleotide polymorphisms in DNA repair genes and prostate cancer risk. Methods Mol Biol (2009) 0.90
Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: a pilot study in north Indian population. BMC Urol (2005) 0.87
Farnesol protects against intratracheally instilled cigarette smoke extract-induced histological alterations and oxidative stress in prostate of wistar rats. Toxicol Int (2013) 0.81
A case of synchronous double malignancy: Invasive bladder cancer and Leiomyosarcoma of extremity and review of literature. South Asian J Cancer (2013) 0.75
Lack of association between NAT2 polymorphism and prostate cancer risk: a meta-analysis and trial sequential analysis. Oncotarget (2017) 0.75
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci U S A (2010) 3.00
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res (2006) 2.23
Clinical management of uterine sarcomas. Lancet Oncol (2009) 2.18
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol (2005) 1.98
Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol (2007) 1.93
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res (2008) 1.80
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med (2011) 1.79
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet (2006) 1.68
PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol (2002) 1.59
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A (2012) 1.51
Higher than expected association of clinical prostate and bladder cancers. J Urol (2008) 1.49
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol (2010) 1.48
Clustering of deletions on chromosome 13 in benign and low-malignant lipomatous tumors. Int J Cancer (2003) 1.45
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res (2012) 1.43
HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in cooperation with nuclear factor-kappaB. Mol Cancer Res (2007) 1.42
Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology (2006) 1.41
Finding unrecognized information in overactive bladder clinical trial data: a new approach to understanding placebo and treatment effects. Neurourol Urodyn (2012) 1.40
Antimuscarinic use among individuals with urinary incontinence who reside in long-term care facilities. Int Urol Nephrol (2013) 1.38
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res (2009) 1.37
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer (2011) 1.36
Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer (2013) 1.29
Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol (2008) 1.28
Other malignant neoplasms in patients with gastrointestinal stromal tumors (GIST). Med Sci Monit (2004) 1.27
Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes Cancer (2007) 1.27
The spectrum of eosinophilic cystitis in males: case series and literature review. Arch Pathol Lab Med (2009) 1.24
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother (2012) 1.24
Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg (2006) 1.23
Extramammary myofibroblastoma is genetically related to spindle cell lipoma. Virchows Arch (2006) 1.21
Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol (2006) 1.21
Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol (2006) 1.21
Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol (2008) 1.20
Uterine gastrointestinal stromal tumour (GIST). Gynecol Oncol (2005) 1.20
Gastrointestinal stromal tumor of the prostate. Urology (2005) 1.19
12p-amplicon structure analysis in testicular germ cell tumors of adolescents and adults by array CGH. Oncogene (2003) 1.18
No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer (2009) 1.18
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Ann Surg Oncol (2011) 1.17
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res (2008) 1.16
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res (2012) 1.16
Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. Neurobiol Dis (2004) 1.15
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res (2009) 1.14
Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol (2013) 1.14
Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res (2011) 1.14
Activation of the GLI oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic neoplasms: pericytoma with t(7;12). Am J Pathol (2004) 1.11
The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol (2012) 1.09
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One (2012) 1.08
Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes. Genes Chromosomes Cancer (2012) 1.07
Adult sclerosing rhabdomyosarcoma: cytogenetic link with embryonal rhabdomyosarcoma. Virchows Arch (2004) 1.06
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. Clin Cancer Res (2012) 1.05
Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res (2010) 1.05
DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies. Cancer Res (2008) 1.04
Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. BJU Int (2008) 1.04
Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. Gastroenterology (2006) 1.03
Characterization of prostate cancer missed by sextant biopsy. Clin Prostate Cancer (2003) 1.03
Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. Anticancer Res (2006) 1.03
Multiple primary sporadic gastrointestinal stromal tumors in the adult: an underestimated entity. Clin Cancer Res (2008) 1.03
High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res (2009) 1.02
The role of prevalence in the diagnosis of prostate cancer. Cancer Control (2006) 1.02
Role of gain of 12p in germ cell tumour development. APMIS (2003) 1.01
Epidemiology of prostate cancer in Africa: another step in the understanding of the disease? Curr Probl Cancer (2007) 1.01
Recurrent rearrangement of the PHF1 gene in ossifying fibromyxoid tumors. Am J Pathol (2012) 0.99
Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res (2010) 0.98
Higher than expected association of clinical prostate and bladder cancers. J Urol (2005) 0.97
Gastrointestinal stromal tumors: key to diagnosis and choice of therapy. Mol Diagn Ther (2008) 0.97
Saturation biopsies for prostate cancer: current uses and future prospects. Nat Rev Urol (2009) 0.95
Cytokeratin-positive meningeal peripheral PNET/Ewing's sarcoma of the cervical spinal cord: diagnostic value of genetic analysis. Int J Surg Pathol (2005) 0.95
Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J Cancer Res Clin Oncol (2007) 0.95
KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs). Biochim Biophys Acta (2005) 0.95
Inflammatory myofibroblastic tumor with ALK/TPM3 fusion presenting as ileocolic intussusception: an unusual presentation of an unusual neoplasm. Hum Pathol (2005) 0.94
Identification of a karyopherin alpha 2 recognition site in PLAG1, which functions as a nuclear localization signal. J Biol Chem (2002) 0.94
Chondroid lipoma is characterized by t(11;16)(q13;p12-13). Virchows Arch (2004) 0.93
The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. Clin Cancer Res (2011) 0.93
The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Mol Cancer Ther (2011) 0.92
Mesenteric lipoblastoma presenting as a segmental volvulus. J Pediatr Surg (2009) 0.92
Frequent activation of EGFR in advanced chordomas. Clin Sarcoma Res (2011) 0.92
ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol (2004) 0.92
Primary epithelioid sarcoma of the oesophagus. Virchows Arch (2007) 0.92
Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol (2004) 0.91
The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis. Cancer Res (2013) 0.91
Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer (2004) 0.90
Extramammary myofibroblastoma in the head and neck region. Head Neck (2009) 0.89
Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation. Arch Pathol Lab Med (2007) 0.89
Molecular cytogenetic characterization of proximal-type epithelioid sarcoma. Genes Chromosomes Cancer (2004) 0.89
FOSL1 as a candidate target gene for 11q12 rearrangements in desmoplastic fibroblastoma. Lab Invest (2012) 0.89
From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae. Breast Dis (2004) 0.88
Case report of a poorly differentiated uterine tumour with t(10;17) translocation and neuroectodermal phenotype. Anticancer Res (2011) 0.87
Association of prostate cancer and manganese superoxide dismutase AA genotype influenced by presence of occult cancer in control group. Urology (2008) 0.87
Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: description of three new cases. Tumour Biol (2012) 0.86
Comparison of ante- and post-mortem PSA levels for epidemiological studies. Anticancer Res (2005) 0.86
Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. Semin Oncol (2009) 0.86
Rearrangement of the COL12A1 and COL4A5 genes in subungual exostosis: molecular cytogenetic delineation of the tumor-specific translocation t(X;6)(q13-14;q22). Int J Cancer (2006) 0.86
The t(X;6) in subungual exostosis results in transcriptional deregulation of the gene for insulin receptor substrate 4. Int J Cancer (2011) 0.86
Lipoblastoma in a 23-year-old male: distinction from atypical lipomatous tumor using cytogenetic and fluorescence in-situ hybridization analysis. Virchows Arch (2003) 0.86
The presence of carboxypeptidase-M in tumour cells signifies epidermal growth factor receptor expression in lung adenocarcinomas: the coexistence predicts a poor prognosis regardless of EGFR levels. J Cancer Res Clin Oncol (2007) 0.86
Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies. Cancer Invest (2010) 0.85
Biallelic inactivation of NF1 in a sporadic plexiform neurofibroma. Genes Chromosomes Cancer (2012) 0.85